Two phase III randomized trials, FLAURA 2 and Mariposa [18,19], have recently produced clinically relevant data on this topic that open new perspectives and possibilities in the treatment algorithms for EGFR mutant NSCLC patients (Table 1 and Table 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.